SYDNEY, March 12, 2014 /PRNewswire/ -- Novogen
Limited (ASX: NRT; NASDAQ: NVGN), an oncology drug development
company, today announced that Graham
Kelly, Ph.D., Executive Director and Chief Executive
Officer, will present at the 2nd Annual Sachs Cancer Bio
Partnering & Investment Forum. Dr. Kelly's presentation will
take place at 2:30 p.m. on
Wednesday, March 19, 2014 at the New
York Academy of Sciences in New York
City.
About Novogen Limited
Novogen is a public, Australian
biotechnology company whose shares trade on both the Australian
Securities Exchange ('NRT') and NASDAQ ('NVGN'). The Company
is based in Sydney, Australia, and
with a U.S. office in New Haven,
Connecticut. The Company has two main drug technology
platforms known as super-benzopyrans (SBP) and anti-tropomyosins
(ATM). SBP drugs target cancer stem cells and are being developed
for the treatment of ovarian cancer and glioblastoma. ATM drugs
target the cancer cell cytoskeleton and are being developed for the
treatment of melanoma, prostate cancer and neuroblastoma. Novogen
has entered into a joint venture with Yale
University known as CanTx Inc. with the aim of developing
personalized chemotherapy for patients with ovarian cancer.
Further information is available on the Company's website,
www.novogen.com.
For Further Information Contact:
|
Investors
|
Media
|
|
|
|
In the USA
|
In the USA
|
|
David Carey/Tanner
Kauffman
|
Hollister Hovey/Allison
Parks
|
|
Lazar Partners
|
Lazar Partners
|
|
+1 212-867-1762
|
+1 212-867-1762
|
|
Novogen@lazarpartners.com
|
Novogen@lazarpartners.com
|
|
|
|
In Australia
|
In Australia
|
|
Rudi Michelson
|
Dr Douglas Pretsell
|
|
Monsoon
Communications
|
Instinctif Partners
|
|
03 9620
3333
|
+61(0)3 9657
0706
|
|
rudim@monsoon.com.au
|
|
|
|
|
In
ROW
|
|
Sue Charles/Stefanie
|
|
Instinctif Partners
|
|
+44 (0)20 7457
2020
|
Logo -
http://photos.prnewswire.com/prnh/20131220/NY36990LOGO
SOURCE Novogen Limited